Sanofi and Hanmi Pharmaceutical Co. Ltd announced a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.
Under the terms of the agreement, Hanmi
will receive an upfront payment of €400 million and is eligible for up
to €3.5 billion in development, registration and sales milestones, as
well as double digit royalties on net sales. Sanofi will obtain an
exclusive worldwide license to develop and commercialize 1.)
efpeglenatide, a late-stage long-acting glucagon-like peptide-1 receptor
agonists (GLP1-RA); 2.) a weekly insulin and 3.) a fixed-dosed weekly
GLP-1-RA/insulin drug combination. Collectively, these therapeutic
offerings are known as the "Quantum Project" utilizing Hanmi's
proprietary Long Acting Protein / Peptide Discovery Platform LAPSCOVERY
technology. Hanmi will retain an exclusive option to co-commercialize
the products in Korea and China.
The Quantum Portfolio is based on Hanmi's proprietary LAPSCOVERY (Long
Acting Protein/Peptide Discovery) Technology which is a platform
technology that prolongs the duration of action of biologics. The
objective is to minimize the frequency of treatment and the dose
required, thereby potentially lowering the adverse event rates and
optimizing efficacy, according to Hamni.
